Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12893
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJamieson, Gary Pen
dc.contributor.authorSnook, M Ben
dc.contributor.authorBradley, T Ren
dc.contributor.authorBertoncello, Ien
dc.contributor.authorWiley, J Sen
dc.date.accessioned2015-05-16T02:38:39Z
dc.date.available2015-05-16T02:38:39Z
dc.date.issued1989-01-15en
dc.identifier.citationCancer Research; 49(2): 309-13en
dc.identifier.govdoc2910450en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/12893en
dc.description.abstract1-beta-D-Arabinofuranosylcytosine (araC) is an effective drug in the i.p. therapy of ovarian carcinoma but little is known of its transport and metabolism in this tumor. Influx of araC at 1 microM into cultured human ovarian carcinoma cells (CI 80-13S) was largely inhibited by nanomolar concentrations of the nucleoside transport inhibitor, nitrobenzylthioinosine, while the residual influx (approximately 10%) was inhibited only by micromolar concentrations of nitrobenzylthioinosine. There was a two fold greater density of specific [3H]nitrobenzylthioinosine binding to the nucleoside transporters on the ovarian than on cultured human leukemic cells (RC2a). Calculated turnover rates of the nucleoside transporter for 1 microM araC were 5-fold less in ovarian than in leukemic cells. The major metabolic product of araC was 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (araCTP) which accumulated in the ovarian cells to levels half those achieved in the leukemic cells. AraC was the major product of araCTP degradation in ovarian cells consistent with a pathway (araCTP--------araCMP----araC) which is different from that previously found in leukemic cells (araCTP--------araCMP----araUMP----araU). Despite these differences, ovarian carcinoma cells show substantial accumulation of araCTP from extracellular araC.en
dc.language.isoenen
dc.subject.otherAdenocarcinoma.metabolismen
dc.subject.otherAgeden
dc.subject.otherArabinofuranosylcytosine Triphosphate.metabolismen
dc.subject.otherBinding Sitesen
dc.subject.otherCell Lineen
dc.subject.otherCytarabine.metabolismen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherLeukemia, Myelomonocytic, Acute.metabolismen
dc.subject.otherMaleen
dc.subject.otherOvarian Neoplasms.metabolismen
dc.subject.otherThioinosine.analogs & derivatives.metabolismen
dc.titleTransport and metabolism of 1-beta-D-arabinofuranosylcytosine in human ovarian adenocarcinoma cells.en
dc.typeJournal Articleen
dc.identifier.journaltitleCancer researchen
dc.identifier.affiliationDepartment of Haematology, Austin Hospital, Heidelberg, Melbourne, Australiaen
dc.description.pages309-13en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/2910450en
dc.type.austinJournal Articleen
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.